ELVN
Enliven Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$52.80-0.75%
Price as of Jul 20, 2026
ELVN ownership
Enliven Therapeutics, Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
23
Net (3m)
-$53.5M
Insider trades by month Buys Sells
Feb
Mar
Apr
May
Jun
Jul
Context3-month price +13.4%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 8, 2026 | Kunkel Lori Annedirector | Sell | 4,111 | $49.98 |
| Jul 8, 2026 | Kunkel Lori Annedirector | Sell | 5,889 | $50.84 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 46,776 | $45.00 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 24,846 | $45.38 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 1,477 | $45.00 |
| Jun 24, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 787,024 | $45.38 |
| Jun 22, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 2,599 | $43.87 |
| Jun 22, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 1,268 | $42.83 |
| Jun 22, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| Jun 22, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Option | 6,018 | $2.48 |
| Jun 22, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 1,379 | $42.78 |
| Jun 22, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 3,401 | $43.86 |
| Jun 22, 2026 | Hohl Benjaminofficer: CHIEF FINANCIAL OFFICER | Sell | 1,238 | $44.75 |
| Jun 22, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 1,133 | $44.74 |
| Jun 17, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 9,086 | $45.02 |
| Jun 17, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 272,322 | $45.02 |
| Jun 9, 2026 | Kunkel Lori Annedirector | Sell | 1,867 | $35.36 |
| Jun 9, 2026 | Kunkel Lori Annedirector | Sell | 7,779 | $34.28 |
| Jun 9, 2026 | Kunkel Lori Annedirector | Sell | 354 | $35.82 |
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 1,302 | $40.25 |
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 223 | $41.21 |
| May 20, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 3,475 | $39.53 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 5,000 | $2.48 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 2,419 | $47.39 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 2,441 | $48.06 |
| Apr 21, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 140 | $45.81 |
| Mar 27, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 40,000 | $35.10 |
| Mar 27, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Option | 40,000 | $2.48 |
| Mar 19, 2026 | Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $27.76 |
Source: ELVN SEC Form 4 filings, latest Jul 8, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their ELVN positions over the last 6 months (SEC Form 13F).
Increased
110
New positions
88
Reduced
77
Sold out
46
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 8.0M | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 8.0M | May 15, 2026 |
| FMR LLC | Reduced | 7.1M | Feb 17, 2026 |
| FMR LLC | Reduced | 6.8M | May 15, 2026 |
| POLAR CAPITAL HOLDINGS PLC | Increased | 5.1M | May 15, 2026 |
| COMMODORE CAPITAL LP | Unchanged | 4.7M | Feb 17, 2026 |
| VESTAL POINT CAPITAL, LP | Increased | 3.8M | Feb 17, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 3.7M | Feb 17, 2026 |
| BLACKROCK, INC. | Increased | 3.7M | May 13, 2026 |
| BLACKROCK, INC. | Increased | 3.6M | Feb 12, 2026 |
| POLAR CAPITAL HOLDINGS PLC | Increased | 3.5M | Feb 17, 2026 |
| COMMODORE CAPITAL LP | Reduced | 3.3M | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | Reduced | 3.3M | May 15, 2026 |
| VR ADVISER, LLC | Unchanged | 3.2M | Feb 17, 2026 |
| VANGUARD GROUP INC | Increased | 2.8M | Jan 29, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.